Exogenous p27KIP1 expression induces anti-tumour effects and inhibits the EGFR/PI3K/Akt signalling pathway in PC3 cells

Asian Journal of Andrology

Volumn 11, Issue 6, 2009, Pages 669-677

  Chen, Jun ^a   Xia, Dan ^a   Luo, Jin Dan ^a   Wang, Ping ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P27; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOLECULAR MECHANICS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 71049162928     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2009.51     Document Type: Article

References (39)

1. Sherwood ER, Van Dongen JL, Wood CG, Liao S, Kozlowski JM, et al. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. Br J Cancer 1998; 77: 855-61.
2. Davies P, Eaton CL, France TD, Phillips ME. Growth factor receptors and oncogene expression in prostate cells. Am J Clin Oncol 1988; 11 (Suppl 2): S1-7.
3. Festuccia C, Gravina GL, Angelucci A, Millimaggi D, Muzi P, et al. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer 2005; 115: 630-40.
4. Eder IE, Bektic J, Haag P, Bartsch G, Klocker H. Genes differentially expressed in prostate cancer. BJU Int 2004; 93: 1151-5.
5. Katner AL, Hoang QB, Gootam P, Jaruga E, Ma Q, et al. Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27 (Kip1). Prostate 2002; 53: 77-87.
6. Ye D, Mendelsohn J, Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res 1999; 5: 2171-7.
7. Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, et al. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. J Cell Physiol 2004; 201: 97-105.
8. Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 2002; 7: D376-89.
9. Patel T, Gores GJ, Kaufmann SH. The role of proteases during apoptosis. FASEB J 1996; 10: 587-97.
10. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006; 27: 1-22.
11. Martinez LA, Chen Y, Fischer SM, Conti CJ. Coordinated changes in cell cycle machinery occur during keratinocyte terminal differentiation. Oncogene 1999; 18: 397-406.
12. Craig C, Wersto R, Kim M, Ohri E, Li Z, et al. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 1997; 14: 2283-9.
13. Sgambato A, Zhang YJ, Ciaparrone M, Soh JW, Cittadini A, et al. Overexpression of p27Kip1 inhibits the growth of both normal and transformed human mammary epithelial cells. Cancer Res 1998; 58: 3448-54.
14. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998; 58: 542-8.
15. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159: 941-5.
16. Katner AL, Gootam P, Hoang QB, Gnarra JR, Rayford W. A recombinant adenovirus expressing p27(Kip1) induces cell cycle arrest and apoptosis in human 786-0 renal carcinoma cells. J Urol; 168: 766-73.
17. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, et al. Promoting apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997; 57: 5441-5.
18. Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJ. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). J Clin Invest 1999; 103: 597-604.
19. Wang X, Gorospe M, Huang Y, Holbrook NJ. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997; 15: 2991-7.
20. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, et al. Overexpression of bcl-2 protects cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438 -45.
21. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156: 1511-6.
22. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4.
23. Thornberry NA, Lazebnik Y. Caspase: Enemies within. Science 1998; 281: 1312-6.
24. Kaplan PJ, Leav I, Greenwood J, Kwan PW, Ho SM. Involvement of transforming growth factor alpha (TGFalpha) and epidermal growth factor receptor (EGFR) in sex hormone-induced prostatic dysplasia and the growth of an androgen-independent transplantable carcinoma of the prostate. Carcinogenesis 1996; 17: 2571-79.
25. Gil-Diez de Medina S, Salomon L, Colombel M, Abbou CC, Bellot J, et al. Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol 1998; 29: 1005-12.
26. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002; 8: 3438-44.
27. Mimeault M, Pommery N, Wattez N, Bailly C, Henichart JP. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: Implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 2003; 56: 1-12.
28. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 2000; 19: 1647-56.
29. Mimeault M, Pommery N, Henichart JP. New advances on prostate carcinogenesis and therapies: Involvement of EGFEGFR transduction system. Growth Factors 2003; 21: 1-14.
30. Torring N, Dagnaes-Hansen F, Sorensen BS, Nexo E, Hynes NE. ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate 2003; 56: 142-9.
31. Mimeault M, Moore E, Moniaux N, Henichart JP, Depreux P, et al. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer 2006; 118: 1022-31.
32. Bonaccorsi L, Marchiani S, Muratori M, Forti G, Baldi E. Gefitinib. ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3K/AKT activation. J Cancer Res Clin Oncol 2004; 130: 604-14.
33. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26: 263-73.
34. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, et al. Prostste cancer cell cycle regulators: Reponse to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999; 91: 1869-76.
35. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-68.
36. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, et al. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 1999; 398: 630-4.
37. Sastry KS, Smith AJ, Karpova Y, Datta SR, Kulik G. Diverse anti-apoptotic signaling pathways activated by VIP, EGF and PI3K in prostate cancer cells converge on BAD. J Biol Chem 2006; 281: 20891-901.
38. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK- mediated mitochondrial apoptosis. Mol Cell 2001; 8: 70511.
39. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-30.